Shenzhen Kangtai Biological Products Co Ltd

The company maintains a strong liquidity position, with a current ratio of 2.71, indicating sufficient short-term assets to cover liabilities. However, its free cash flow is negative at -20.43 million CNY, and capital expenditures are substantial at -331.92 million CNY, suggesting ongoing investment in operations. The debt-to-equity ratio is 0.19, reflecting a conservative capital structure with limited leverage.

Profitability metrics show a return on equity of 0.73% and a return on assets of 0.5%, both below the typical thresholds for pharmaceutical firms, which often aim for ROE above 10% and ROA above 5%. The net income of 70.33 million CNY is modest relative to total assets of 14.10 billion CNY, indicating low asset utilization efficiency.

Geographic and segment exposure is not explicitly detailed in the available data, but the company operates primarily in China, with revenue concentrated in domestic markets. No material international operations or segment-specific revenue breakdowns are disclosed.

The company’s growth trajectory is constrained, with no specific revenue growth rates or outlooks provided. Analysts have assigned a mean price target of 16.44 CNY, with a median of 15.50 CNY, and a mean recommendation of 2.33 (leaning toward hold). No significant revenue acceleration is evident from the financial snapshot.

Risk factors include medium liquidity risk due to negative net cash after subtracting total debt, and a low dilution risk, with no near-term pressure from share issuance. The company’s capital expenditures and free cash flow suggest reinvestment in operations, but no dilution sources are explicitly disclosed.

Recent events include no notable filings or transcripts in the provided data. Analysts have issued one strong-buy recommendation and two holds, with no buy or strong-sell ratings, indicating a cautious outlook.